MCK retail buzz rises as analysts lift targets ahead of November print

McKesson shares are up 14.2% over the past month, trading at $1,012. Retail attention has jumped to 2.95 standard deviations above its 90-day average, per Wikipedia views and ORTEX stock page data. That spike in attention arrives alongside a cluster of analyst target increases and an earnings date just 12 days away.

Analysts keep raising the bar

Three firms have lifted their price targets on McKesson in the past two weeks alone. UBS raised its target from $1,080 to $1,200 while keeping a Buy rating, the highest target in the recent batch. Mizuho moved its target from $905 to $1,020, maintaining Neutral. Leerink Partners raised to $1,070 from $1,030, keeping Outperform. The consensus target sits at $1,009.64, fractionally below the current price, meaning the street as a whole has not yet caught up with October's move.

The bull case centres on specialty drug growth. GLP-1 distribution and oncology volumes have driven stronger-than-expected revenue, with specialty drugs on track to represent over 55% of drug spending by 2028. Seven to eight of every ten new drug approvals are classified as specialty.

The bear case is more specific. GLP-1 prior authorizations account for roughly 9.5% to 11.5% of Retail and Specialty revenue. Six percent of large employers dropped GLP-1 coverage in 2026, and another 10% plan to do so in 2027. IRA drug price negotiations in 2028 could cut prices 40% to 60% on about $28 billion of Medicare drug spend.

Medicaid volumes back the distribution story

ORTEX Alt Data tracks Medicaid drug utilisation via Centers for Medicare and Medicaid Services data. Medicaid units reimbursed rose 78% in Q1 2026 against the same quarter a year earlier, reaching nearly 25 million units. That marks three consecutive quarters of growth in reimbursed volumes. None of the five alt datasets tracked for McKesson have been measured as a leading indicator of the company's reported financials, so the Medicaid figures are context rather than a read-through to the November print.

Short interest and borrow market: nothing urgent

Short interest stands at 1.82% of free float, near historic lows for the stock, and fell 6.9% over the past week. The borrow market is exceptionally loose: over 81 million shares remain available to lend. Cost to borrow is 0.375%, up 58% on the week, but the absolute level is still negligible. There is no sign of meaningful short-side conviction here.

Insider activity over the past 90 days shows net sales of roughly $1.2 million in value, almost entirely under pre-arranged 10b5-1 plans. CEO Brian Tyler sold shares in June and July under such a plan. Planned sales carry less signal than discretionary ones.

What to watch

McKesson reports on 4 November. The key number to track ahead of that date is GLP-1 prior authorisation revenue as a share of Retail and Specialty revenue. Any employer coverage data released between now and then will sharpen the debate between the UBS $1,200 target and the RBC $845 Sector Perform.

---

Data summary

• Price: $1,012.34, up 14.2% over one month
• Short interest: 1.82% of free float, down 6.9% over one week
• Shares available to borrow: 81.7 million
• Cost to borrow: 0.375%, up 58% on the week
• Retail attention z-score: 2.95 vs 90-day average (Wikipedia and ORTEX page data, as of 22 October)
• Medicaid units reimbursed: up 78% year on year in Q1 2026 (CMS data)
• UBS target: $1,200. Mizuho target: $1,020. Leerink target: $1,070
• Next earnings: 4 November 2026